Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ejh.13829 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T-cell pathway in patients with diffuse large B-cell lymphoma.
Hematol Oncol
December 2023
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Pixantrone as a bridge to CAR-T treatment in high-grade transformation of follicular lymphoma.
Eur J Haematol
November 2022
Department of Haematology, Beaumont Hospital, Dublin, Ireland.
Rescue Therapy of Refractory Diffuse Large B-Cell Lymphomas BCL2 with Venetoclax: Case Report.
Chemotherapy
March 2021
Department of Mental and Physical Health and Preventive Medicine, Pathology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
Eleven years ago, a 64-year-old Caucasian man had LNH Follicular 3a, IV A stage, FLIPI 2 as a prognostic index of follicular lymphoma. He received 8 cycles of RCHOP followed by rituximab maintenance, with complete remission. Due to a systemic recurrence, a new treatment schedule (RCOMP, 6 cycles) was introduced with partial remission persisting during a long-term maintenance treatment with rituximab.
View Article and Find Full Text PDFSingle-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma.
Chemotherapy
May 2017
Oncology-Hematology Unit, ASST Valle Olona, Busto Arsizio, Italy.
Article Synopsis
- Aggressive non-Hodgkin lymphoma typically leads to poor long-term survival after chemotherapy relapse, as seen in a patient resistant to standard treatments R-CHOP and R-DHAP.
- The patient achieved remission with the use of pixantrone, followed by high-dose BEAM chemotherapy and autologous stem cell transplantation to consolidate treatment.
- After 20 months post-transplant, the patient remains in continuous complete remission, demonstrating the effectiveness of pixantrone with minimal side effects.
Pixantrone is a novel aza-anthracenedione active against aggressive lymphoma and is being evaluated for use against various hematologic and solid tumors. The drug is an analog of mitoxantrone, but displays less cardiotoxicity than mitoxantrone or the more commonly used doxorubicin. Although pixantrone is purported to inhibit topoisomerase II activity and intercalate with DNA, exact mechanisms of how it induces cell death remain obscure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!